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ABSTRACT 
Objective: The aim of this study was to determine the occurrence of latent TB infections (LTBI) and 
active Tuberculosis (TB) in a cohort of inflammatory bowel disease (IBD) patients treated with 
biologics. We also examined the effects of immunosuppressive drugs on indeterminate interferon-
gamma release assays (IGRA) in LTBI screening. 
Design: Retrospective study of patients treated with biologics between March 2007 and November 
2015. 
Setting: St Mark’s Hospital, North West London, UK. 
Patients: 732 patients with IBD who were screened for LTBI using either TST or IGRA before starting 
a biological treatment. 
Methods: Retrospective case note review of all IBD patients who were screened for LTBI prior to 
initiating biologics. Patients who developed active TB were identified from the London TB register. 
Results: Of 732 IBD patients, 31 (4.2%) were diagnosed with and treated for LTBI with no significant 
side effects. Six of 596 patients (1.0%) who received biologic treatment developed active TB. There 
was a higher proportion of indeterminate IGRA in the immunosuppressive medication group 
compared to the non-immunosuppressive group (33% (59/181) compared to 9% (6/66), p<0.001). 
The combination of steroids and thiopurines had the highest proportion of indeterminate IGRA 
(64%, 16/25). High and low doses of steroids were equally likely to result in an indeterminate IGRA 
result (67% (8/12) and 57% (4/7), respectively). 
Conclusions: This study highlights the challenges of LTBI screening prior to commencing biologic 
therapy, and demonstrates the risk of TB in patients who have been screened and who are receiving 
prolonged and continuing doses of anti-TNF. 
  
  
SIGNIFICANCE OF THIS STUDY 
What is already known about this subject? 
Biologic treatment for IBD carries an increased risk of TB. 
Concomitant treatment with steroids can affect IGRA results. 
What are the new findings? 
This is the first large retrospective study in the UK of the incidence of LTBI and active TB in IBD 
patients treated with biologics. 
We have identified the relationship between an indeterminate IGRA and immunosuppressive drugs 
used for IBD treatment. 
We have highlighted the importance of vigilance for active TB in patients treated with biologics. 
How might it impact on clinical practice in the foreseeable future? 
This study may support new strategies in screening for LTBI in patients on immunosuppressive drugs 
for IBD. 
This study demonstrates the need for vigilance for the development of active TB in IBD patients on 
biologics, even if deemed of low epidemiological risk. 
  
INTRODUCTION 
Biologic treatments, such as anti-tumour necrosis factor (anti-TNF) therapies, have led to significant 
improvements in outcomes for patients with inflammatory bowel disease (IBD), but are associated 
with an increased risk of Mycobacterium tuberculosis (TB) infection [1]. Individual risk of developing 
M. tuberculosis infection is influenced by the type of biologic drug, concomitant immunosuppressive 
therapies and other epidemiological factors [2]. Identifying and treating latent TB infection (LTBI) 
and active TB in the context of biologic therapy is challenging, because the altered immune response 
gives rise to atypical presentation such as extra-pulmonary and disseminated mycobacterial disease 
[1]. 
The European Crohn’s and Colitis Organisation (ECCO) recommend that, before commencing biologic 
treatment, screening for LTBI should be undertaken using a combination of history, chest X-ray 
(CXR), and tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) according to local 
prevalence of TB, national guidance and BCG status [3]. TST and IGRA have limitations in diagnosing 
LTBI, including increased false negatives among immunosuppressed patients [4]. 
Although specificity for diagnosing LTBI using IGRAs is reported as 95%, there are issues around 
reproducibility and indeterminacy of test results [5]. Indeterminate results can occur in 2% of the 
healthy population [5], and in up to 12% of immunocompromised or immunosuppressed patients 
[6]. Whilst it is known that concomitant treatment with steroids can affect IGRA test results, less is 
known about the effects of other immunosuppressive medications. Indeterminate IGRA results in 
the context of possible LTBI may delay the initiation of biologic treatment because of the need for 
repeat testing and consultation with TB services.  
The primary aim of this study was to determine rates of LTBI in our IBD cohort treated with biologics 
by two screening methods - TST (to July 2013) and IGRA (from July 2013). Secondary aims were to 
determine the effects of different immunosuppressive drugs on the frequency of indeterminate 
IGRA test results, and to review cases of active TB which developed during biologic treatment. 
  
METHODS 
St Mark’s Hospital is a national and international referral centre for patients with IBD in North West 
London, UK. It is part of London North West Healthcare NHS Trust, which serves an ethnically diverse 
population from the London boroughs of Brent, Harrow and Ealing. Local TB rates are up to 82.9 per 
100,000, compared to a London wide average of 13.5 per 100,000 [7].  
We conducted a retrospective case note review of all IBD patients who were screened prior to 
initiating biologics between March 2007 and November 2015. Patients were identified from the 
high-cost funding database held at St Mark’s Hospital pharmacy. Data were collected from the 
hospital electronic patient information system, the radiology PACS (Picture Archiving and 
Communication System), and the Integrated Clinical Environment (ICE) test results system, and by 
reviewing available hand-written patient notes. 
LTBI screening information was obtained from risk assessment templates, x-ray reports, and TST or 
IGRA test results. Of note, in July 2013 IGRA testing replaced TST in the LTBI screening algorithm. For 
patients diagnosed with LTBI, the nature of their IBD treatment and LTBI treatment (either isoniazid 
alone for six months or combined rifampicin and isoniazid for 3 months) was recorded, including any 
adverse events. Drug-induced liver injury (DILI) was defined as an alanine aminotransferase (ALT) 
rise of 5 times the upper limit of normal (ULN) without symptoms or 3-5 times the ULN with 
symptoms. Patients who developed active TB were identified from the London TB register. The Chi-
squared test was used to compare categorical data, including the effect of immunosuppressive 





During the study period, 732 patients with IBD who were considered for starting a biological 
treatment were screened for LTBI with either a TST or IGRA. Of these 732 patients, 485 (66.3%) were 
screened with a TST of whom 23/485 (4.7%) were positive, and 247 (33.7%) were screened with an 
IGRA of whom 6/247 (2.4%) were positive (Figure 1). The median age was 39 (IQR 21-50) years, 51% 
were male, 76% had Crohn’s disease (CD), 24% had Ulcerative Colitis (UC) and 0.4% had 
Inflammatory Bowel Disease Unclassified (IBDU) (Table 1). 
Table 1: Characteristics of IBD patients (N=732) 
Age (years) - median (IQR) 39 (21 - 50) 
Sex, male - n (%) 373 (50.9%) 
Crohn’s disease - n (%) 556 (76.0%) 
Ulcerative colitis - n (%) 173 (23.6%) 
IBDU - n (%) 3 (0.4%) 
LTBI - n (%) 31 (4.2%) 
Active TB - n (%) 6 (1) 
Biologic treatment - n (%) 596 (81.4%) 
 
Latent TB Infection 
31/732 (4.2%) patients were diagnosed and treated for LTBI during the study period; 23 (74.2%) TST 
positive, 6 (19.4%) IGRA positive, and 2 (6.5%) TST positive after an indeterminate IGRA (Figure 1). 
Of the 31 LTBI patients, 19 (61.3%) received isoniazid alone for six months and 12 (38.7%) had 
combined rifampicin and isoniazid for 3 months; 22/31 (71.0%) patients went on to have anti-TNF 
treatment with a median time to starting treatment of 86 (IQR 56-166) days. Nine patients did not 
receive biologic treatment at St Mark’s hospital for various reasons, including surgery precluding the 
need for biologics, disease improvement or receiving biologic treatment elsewhere. One patient 
treated for LTBI reported dizziness which was not severe enough to warrant stopping treatment. No 
serious adverse events occurred and there were no occurrences of DILI.  
  
IGRA-based LTBI screening 
IGRA replaced TST from July 2013, and 247 patients were screened for TB with an IGRA test. The 
median age was 34 (IQR 25-46) years, 54% (133) were male, 70% (173) had CD and 30% (74) had UC. 
Of the 247 patients screened with IGRA, 208 patients (84.2%) received biologic treatment at St 
Mark’s Hospital. 39/247 patients (16%) were not treated with their biologic treatment at the time of 
study for reasons which included LTBI treatment, surgery or disease improvement. Of 208 patients, 
158 patients (76%) subsequently received Infliximab, 38 (18%) received Adalimumab, 11 (5%) 
Vedolizumab and 1 (0.5%) patient received Golimumab. 
29 IGRA screened patients were referred to the Infectious Diseases team for a specialist TB opinion 
from July 2013 to November 2015 - 6 with a positive IGRA, 17 an indeterminate IGRA and 6 with an 
abnormality on their CXR and a high epidemiological risk for TB despite a negative IGRA. Eight 
patients were treated for LTBI and 1 for active TB. 
The effect of immunosuppressive medications on IGRA 
181/247 (73%) patients were receiving at least one immunosuppressive medication at the time of 
IGRA-based screening. Of 181 patients in the immunosuppressive medication group, 121 (66.8%) 
patients were on thiopurines, 19 (10.4%) on corticosteroids, 25 (13.8%) on corticosteroids and 
thiopurines, 9 (4.9%) on methotrexate, and 7 (3.9%) other immunosuppressive medications.  
Of the 66 patients who were not on any immunosuppressive medications, 2 (3.0%) had a positive 
result, 58 (87.9%) had a negative result and 6 (9.0%) had an indeterminate IGRA result. Repeat 
testing did not change any of the indeterminate results (to positive or negative) (Table 2). 
Among the 181 patients receiving immunosuppressive medication, 4 (2.2%) had a positive IGRA test 
result, 106 (58.6%) a negative result and 72 (39.8%) an indeterminate result. After repeat testing of 
patients with an indeterminate result, a total of 59/181 (32.6%) had an indeterminate result, 
compared with 9% (6/66) of patients not on immunosuppressive medication (p<0.001) (Figure 2). 
  
Patients in each immunosuppressive medication group were more likely to have an indeterminate 
IGRA result, compared to patients not on any immunosuppressive medication: Thiopurines 23.1% 
(28/121, p=0.02); Corticosteroids 42.1% (8/19, p=0.001); Thiopurines and Corticosteroids 64.0% 
(16/25, p<0.001); Methotrexate 44.4% (4/9, p=0.02); other 4(3/7, p=0.04) (Figure 2). 
The effect of steroid dose on IGRA 
Patients on high dose medication (prednisolone >20 mg or intravenous hydrocortisone) had a higher 
proportion of indeterminate IGRA test results - 66.6% (8/12) before repeats, 58.3% (7/12) after 
repeats) - compared to patients on low doses (prednisolone <20 mg or budesonide) - 57.1% (4/7) 
before repeats,  28.6% (2/7) after repeats - but this apparent difference was not supported by 
statistical evidence (Fisher’s exact test, before repeat p=1.00, after repeat p=0.35). 
 
Table 2: Effect of different immunosuppressive medications on IGRA results 
Immunosuppressive medication Number 
of 
patients  
IGRA test result, n (%)  
Positive Negative Indeterminate  
1st test 1st test After repeat 
test 
First test After repeat 
test 
p-value* 
No immunosuppressive 66 2 (3.0%) 58 (87.9%) 58 (87.9%) 6 (9.0%) 6 (9.0%)  
Any immunosuppressive 181 4 (2.2%) 106 (58.6%) 119 (65.7%) 72 (39.8%) 59 (32.6%) <0.001 
Thiopurines  121 2 (1.7%) 84 (69.4%) 92 (76.0%) 36 (29.8%) 28 (23.1%) 0.02 
Corticosteroids 19 1 (5.3%) 6 (31.6%) 10 (52.6%) 11 (57.9%) 8 (42.1%) 0.001 
Thiopurines and corticosteroids  25 1 (4.0%) 8 (32.0%) 8 (32.0%) 16 (64.0%) 16 (64.0%) <0.001 
Methotrexate  9 0 (0.0%) 4 (44.4%) 5 (55.6%) 5 (55.6%) 4 (44.4%) 0.02 
Other* 7 0 (0.0%) 3 (42.9%) 4 (57.1%) 4 (57.1%) 3 (42.9%) 0.04 
* Chi-squared test (Fisher’s exact if cell frequency <5) comparing proportion of indeterminate IGRA test results 
in medication vs. non-medication groups. ‘Other’ included Tacrolimus and Mycophenolate 
 
  
Active TB Patients 
 596 patients received biologic treatment at St Mark’s Hospital during the study period. 6/596 (1.0%) 
developed active TB following the biologic treatment, of whom 5 had CD and 1 had UC. The median 
age was 31 (IQR 26-38) years. Five patients were Caucasian, 1 was born in the UK but of Pakistani 
origin; all were HIV negative; 3 had prior vaccinations for TB, 1 did not and the vaccination status of 
2 was unknown. Five patients had negative TSTs prior to starting biologics, and 1 patient had an 
indeterminate IGRA.   All 6 patients were immunosuppressed at the time of testing and had chest 
imaging prior to biologic treatment. None received LTBI treatment prior to biologic treatment. All 
were deemed to be at low epidemiological risk of TB. 
All patients with active TB had received Adalimumab and Infliximab anti-TNF therapy (3 patients 
receiving Adalimumab had previously been treated with Infliximab) (Table 3). The median time from 
initiation of the most recent anti-TNF therapy to TB diagnosis was 15 (IQR 13-31) months. One 
patient receiving weekly Adalimumab was pregnant and therefore dose frequency was reduced to 
alternate weeks. This patient underwent a Caesarean section at 32-weeks’ gestation and M. 
tuberculosis was later isolated from ascitic fluid samples. The patient returned to theatres day 3 
post-op for further surgery, which demonstrated a caecal mass with a contained perforation; 
histology was in keeping with possible CD and further TB cultures were negative.  
Three patients had culture confirmed TB, 1 was PCR TB complex positive but culture negative and 2 
patients were treated for active TB on the basis of consistent clinical and radiological features. All 
isolated cultures were fully sensitive to the first line therapies. Two patients presented with miliary 
TB, 2 had abdominal TB disease, 1 had pleuro-pulmonary TB, and 1 patient presented with both 
pulmonary and pericardial TB. Treatment duration was for 6 to 12 months depending on the site and 
severity of disease; 5 patients completed treatment and 1 remained on treatment beyond the study 
period.
  
Table 3: Characteristics of IBD patients with active TB 
Age (Sex) Disease Ethnicity Risk Factors 
for TB 
Site of TB Evidence for TB Screening test: result 
(Immunosuppressed 
at time of test) 
Anti-TNF therapy (time since initiation of 
therapy) [Previous Anti-TNF duration] 
49 (F) CD Caucasian  None known Miliary  TST Positive. Multiple interstitial lung 
nodules, ground glass changes and enlarged 
porta hepatitis nodes on CT scan. Liver 
biopsy: granulomatous inflammation. 
TST: Negative (yes) Adalimumab (13 months) 
[Infliximab, 1 dose, allergic reaction on 2nd 
dose] 
  
33 (M) CD Caucasian None known Pulmonary + 
pericardial  
TST positive. Pericardial fluid and induced 
sputum PCR and culture positive for MTB. 
TST: Negative (yes)  Infliximab (41 months) 
  
  
40 (F) CD Caucasian Worked at a 
hospital 
Miliary QTF-G positive. Induced sputum PCR positive 
for MTB. Radiological features of miliary TB 
in lungs on CT scan. 
TST: Negative (yes) Infliximab (35 months) 
  
  
24 (M) UC Pakistani 
(UK born) 
Ethnic origin, 










Infliximab (4 months) 
  
28 (F) CD Caucasian None known Abdominal Ascitic fluid caesarean section culture 
positive for MTB. 
TST: Negative (yes) Adalimumab (13 months) 
[Infliximab, 2 doses, allergic reaction on 3rd 
dose] 
25 (M) CD Caucasian None Known 
  
Abdominal 
lymph node  
Lymph node biopsy: granulomatous 
inflammation. Extensive mesenteric lymph 
nodes on CT abdomen. 
TST: Negative (yes)  Adalimumab (17 months including 5 month 
break for surgery, restarted 3 months prior 
to diagnosis) [Infliximab, 12 months, 
switched due to loss of response] 
  
DISCUSSION 
The overall rate of presumed LTBI in this population receiving biologics for IBD was 4%. Time to start 
biologics after a diagnosis of LTBI at a median of 86 (IQR 56-166) days represents a time lag with 
potential consequences for patients with IBD. ECCO guidelines suggest delaying anti-TNF treatment 
for at least 3 weeks after initiating LTBI chemoprophylaxis; this can be shortened if there is clinical 
urgency for anti-TNF therapy [3]. The timing of starting anti-TNF after initiation of LTBI needs to be 
individualised according to the risk of developing active TB, the risk of hepatotoxicity with LTBI 
treatment, severity of underlying IBD disease and patient choice.  
The incidence of active TB in this cohort was 1%, which was significantly higher than in the average 
UK (12.0/100,000) and London (26.2/100,000) general population [8], but lower than in anti-TNF 
treated patient cohorts in South Korea (2.9%) [9] and Turkey (4.7%) [10]. Our rate for presumed LTBI 
(4%) was also lower than in a Korean cohort of anti-TNF treated patients [11]. These differences 
probably reflect our strategy of active identification of LTBI through screening, and different 
background TB incidence rates. The high incidence of extra-pulmonary TB in our cohort was 
consistent with the other studies [12]. 
Almost one third of IBD patients in our study had an initial indeterminate IGRA test result, of whom 
half had a repeat indeterminate result. An indeterminate IGRA result can indicate failure of the 
positive control, which measures IFN-γ response against phytohaemagglutinin [6], because of a 
reduction in the number and function of T lymphocytes or failure of IFN-γ production [13]. 
Immunosuppressors, which affect this cell-mediated response, can therefore result in a higher 
proportion of indeterminate tests. The proportion of indeterminate IGRAs in patients on 
immunosuppressives was much higher in our study (32%) than in a Swiss IBD cohort (3%), even 
though a similar proportion of patients in each cohort were on immunosuppressive medication (UK 
cohort 73%, Swiss cohort 81%) [14]. An explanation for this difference in indeterminate results 
would require more detailed characterization and comparison of the two cohorts, perhaps including 
  
data to characterise IBD activity, which has been shown to be strongly associated with 
indeterminate IGRAs in paediatric IBD patients [15]. 
The high proportion of indeterminate IGRAs in our patient population suggests that risk 
stratification, including factors such as country of origin and local TB prevalence, may be important 
in the screening of TB prior to biologic therapy in immunosuppressed patients [16]. However, even 
with risk stratification some patients may be missed, as demonstrated by the 6 cases in our study 
who developed active TB, all of whom were deemed to be at low risk of LTBI. This reinforces the 
message that there is no perfect system to identify all patients with LTBI and that vigilance for active 
TB in patients on biologics is required.  
We included patients with IBD who were screened with TST before the introduction of IGRAs to 
obtain an overall estimate of the proportion of patients screened who had LTBI.  TST can be falsely 
negative in immunosuppressed patients [17], therefore we may have underestimated the overall 
prevalence of LTBI. In practice, patients who come from a high TB prevalence country are considered 
for LTBI prophylaxis regardless of their TST or IGRA result.  Whereas TST or IGRA could be used as 
LTBI screening in patients from low TB prevalence area without BCG vaccination [18], early screening 
with IGRA should be considered in immunosuppressed and BCG vaccinated patients [14]. 
Patients on a combination of thiopurines and corticosteroids had the highest proportion of 
indeterminate IGRA results, although all immunosuppressive medications were associated with a 
higher rate of indeterminate IGRAs. This has implications for LTBI screening in IBD patients, given the 
delays associated with indeterminate results. To avoid these delays, LTBI screening could be 
considered prior to commencement of immunosuppressive medication in IBD patients with severe 
ulcerative colitis or Crohn’s disease, or a patient’s baseline risk of LTBI could take precedence over 
IGRA-based screening. This is similar to the approach recommended in British Thoracic Society 
guidelines [19], which were written when TST was the most commonly available LTBI screening test. 
Future guidelines need to take into account indeterminate IGRA results, and give weight to 
  
epidemiological risk. However, given that all active cases of TB in our study were considered to be of 
low epidemiological risk, guidance regarding re-screening strategies might also be needed. For 
example, in treating IBD patients who have been screened and who are receiving prolonged and 
continuing doses of anti-TNF, close liaison with a TB service is advised [20], and even negative IGRA 
test results should not exclude the possibility of LTBI [6]. Any re-screening strategy needs to take 
into account conversion of TB tests and dynamic IGRA responses during anti TNF-treatment [21], and 
should not exclude patients previously treated with biologics [22]. Taken together, such a strategy 
has the potential to reduce, if not eliminate, the risk of patients developing active TB. 
  
FIGURE LEGENDS 
Figure 1: TST and IGRA test results of patients included in this study  
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